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ABSTRACT: Background: Functional dependen-
cy, the need for help in basic activities of daily living, is
an important patient-oriented outcome. We aimed to
describe the development of dependency in Parkinson’s
disease (PD) and identify independent prognostic fac-
tors for this outcome.
Methods: We analyzed data from the Parkinsonism
Incidence in North-East Scotland (PINE) study, a pro-
spective, community-based incident cohort of PD with
ongoing follow-up. We described the development of
dependency defined by a Schwab & England score
of<80% and a Barthel Index of <19. We identified the
baseline predictors of dependency using multivariable
Cox regression.
Results : In 198 patients with PD, the rate of develop-
ment of dependency was 14 per 100 person years.
Older age at diagnosis (hazard ratio for 10-year increase
2.23 [95% confidence interval 1.66-2.98]), greater smok-
ing history (hazard ratio for 10-pack-year increase, 1.15
[1.04-1.26]), more severe axial impairment (hazard ratio
for 5-point increase in sum of axial items from UPDRS
scale, 1.78 [1.30-2.44]), and lower MMSE score (hazard
ratio 0.88 [0.79-0.98]) were independently associated
with a higher risk of dependency as defined by Schwab
& England. Only older age (hazard ratio for 10-year
increase 1.35 [1.04-1.76]) and severity of axial impair-
ment (hazard ratio for 5-point increase 1.85 [1.31-2.62])
were associated with a higher risk of dependency as
defined by the Barthel Index. Sex, deprivation, comor-
bidity, overall UPDRS motor score, and disease stage
were not independently associated with dependency.
Conclus ion: This is the first community-based study
of dependency in PD. There was a high rate of depen-
dency development. Older age, more smoking, more
axial impairment, and poorer cognition were indepen-
dent predictors. VC 2016 The Authors. Movement Disor-
ders published by Wiley Periodicals, Inc. on behalf of
International Parkinson and Movement Disorder Society.
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Functional dependency is an important patient-
oriented outcome that has been infrequently studied in
Parkinson’s disease (PD). In this article, we focus on
dependency in basic daily tasks, defined as being
dependent on others for help with basic activities of
daily living (ADLs), such as walking, washing, dress-
ing, toileting, and feeding. We do not consider other
levels of dependency, such as dependency in instru-
mental ADLs (such as the ability to go shopping, man-
age money, or drive).
In a previous systematic review, we highlighted the
paucity of data on the progression to, and the predic-
tors of, functional dependency.1 Only 2 previous stud-
ies have reported the predictors of dependency:2,3 one
was carried out before and during the early part of
the levodopa era, and both were from specialist clinics
and therefore unlikely to be representative of the gen-
eral population with PD. Neither cohort recruited and
followed patients from the beginning of their disease
course, which is the optimal way to study prognosis.4
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We therefore sought (i) to describe the development
of dependency and (ii) to identify the independent pre-
dictors of the development of dependency in an inci-
dent population-based cohort of PD.
Methods
PINE Study
We analyzed data from the Parkinsonism Incidence in
North-East Scotland (PINE) study, a prospective,
community-based incident cohort of parkinsonism with
ongoing long-term follow-up in Aberdeen, UK. There
were 2 incidence periods: an 18-month pilot phase in an
area with a population of 148,600, beginning Novem-
ber 2002 and a 36-month main study phase in an area
with a population of 317,357 people, beginning April
2006.5-7 We endeavored to identify all patients with a
previously undiagnosed degenerative or vascular par-
kinsonian syndrome using multiple, overlapping strate-
gies for case ascertainment, including writing to general
practitioners and relevant hospital specialists asking
them to refer suspected cases; hand-searching neurology
and geriatric referral letters; and searching general prac-
tice databases and hospital discharge data electronical-
ly. All of the patients who were referred or identified
through the searches and who did not have a previous
diagnosis of a parkinsonian disorder were invited to be
seen by a neurologist with a special interest in move-
ment disorders (or a supervised trainee) for assessment.
We defined incident parkinsonism broadly as either 2 or
more cardinal features (rest tremor, bradykinesia, rigid-
ity, or unexplained postural instability). The only exclu-
sion was drug-induced parkinsonism (defined by
normal dopamine transporter imaging or by complete
resolution of parkinsonism after withdrawal of the rele-
vant drug). All incident patients were invited to consent
to long-term annual follow-up. The study was approved
by the Multi-Centre Research Ethics Committee for
Scotland and conducted with the informed consent of
the patients involved.
This analysis was restricted to patients with idio-
pathic PD. At baseline and at each annual review,
diagnoses were reviewed on the basis of clinical histo-
ry, examination, and imaging findings. PD was defined
by the UK PD Brain Bank criteria8 insofar as follow-
up duration permitted the supportive criteria to be
applied. The latest diagnoses (after follow-up between
5 and 11 years), including postmortem data (available
for 10% of the whole cohort), were used for diagnos-
tic classification for this analysis.
Outcome Definition
Functional dependency was defined by both the
Schwab & England (S&E) scale9 and the Barthel
index10 at annual follow-up visits (some patients had
interim visits, when clinically required, at which S&E
data were also collected). For the survival analyses
reported in this article, we used sustained dependency
as the outcome so only patients who remained depen-
dent for the rest of their follow-up were defined as
having dependency, and patients who were dependent
at 1 visit but subsequently were independent were not
classified as being dependent at that time point.
The S&E scale is an 11-point scale of ability to per-
form activities of daily living, ranging from 100%
(completely independent) to 0% (vegetative) in 10%
increments. Dependency was defined as an S&E score
less than 80% (80%5 completely independent in most
chores; 70%5 not completely independent). Although
the word chores is open to interpretation, we consis-
tently interpreted this as basic ADLs at each time the
scale was used. The S&E scale has been partly validated
for use in PD as a measure of ADLs with evidence of
satisfactory construct validity,11 adequate longitudinal
validity,12 good test-retest reliability,13 and adequate
interrater reliability.14 However, its validity as a dichot-
omous measure of dependency or independency has not
been established. Nevertheless, it does have face validity
for this purpose. The S&E scale was assessed by clini-
cians and was available from all patients.
The Barthel Index is a 20-point scale that rates the
level of dependency for specific basic ADLs. Its validi-
ty and reliability have been demonstrated in many dis-
eases,10 although only 1 small study has reported its
validity in PD.15 Different levels have been used as a
cutoff for defining dependency with this scale, but we
have followed Shah’s description16 of 20 as no depen-
dency and 19 as “slight dependency” and used a score
of 18 or less as our cutoff for dependency. In this
study, the Barthel index was self-reported and was
available only from a subset of patients who consented
to a higher level of study involvement.
Predictor Variables
To avoid overfitting the model, we selected potential
predictors measured at baseline (at diagnosis), which
we thought were likely to be associated with both PD
and dependency, on the basis of previously reported
associations,1 a previous analysis of motor predictors
in the PINE study,17 and clinical knowledge. We
decided that age should be included in the model irre-
spective of statistical significance because of strong
evidence from previous studies that it is associated
with multiple prognostic outcomes. The other candi-
date baseline variables were selected using a backward
stepwise selection process: sex, DepCat (an area-based
deprivation score),18 whether the patient lived alone,
pack years of smoking history, Charlson comorbidity
score,19 severity of bradykinesia (sum of bradykinesia
items from the UPDRS motor score), severity of axial
features (sum of axial items from the UPDRS motor
score), UPDRS part III overall score, MMSE score,
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and Hoehn & Yahr stage. For 98 patients who devel-
oped sustained dependency (measured by the S&E
scale), this represents an events-per-variable ratio of
about 10, the recommended minimum.20 Condensing
comorbidity data into a single index was necessary for
statistical efficiency,21 but it does result in the loss of
information about individual comorbidities.
Statistical Analyses
Using each scale in turn to define dependency, we
plotted Kaplan–Meier curves of survival free from sus-
tained dependency, calculated median duration of
independence, and rates of development of sustained
dependency. Patients who were dependent at the time
of diagnosis were excluded. Patients who died or were
lost to follow-up prior to becoming dependent were
censored at the time they were last seen. Patients
remaining alive and independent were censored at the
time of their last visit up until 19 January 2015. Inde-
pendent predictors of dependency were identified using
Cox regression. First, univariable analysis was per-
formed with each candidate predictor in turn. Then
those variables with association with dependency
(P< .2) were included in a backward stepwise regres-
sion model. A probability cutoff of .1 was used for
the removal of variables from the model (other than
age). Functional form was tested by assessing whether
a 2-power fractional polynomial provided a better
fit.22 The proportional hazards assumption was exam-
ined using tests based on Schoenfeld residuals.23 The
influence of individual observations on the models was
assessed by calculating the likelihood displacement.
One patient was excluded from the model of depen-
dency defined by the S&E scale because of high influ-
ence on the model.
All statistical analyses were performed with Stata
version 12.1 (StataCorp LP, College Station, Texas).
Results
A total of 198 patients with idiopathic PD con-
sented to follow-up (see Fig. 1 and Table 1). All
patients had S&E data, but 32 (16%) did not consent
to the higher level of study involvement, which includ-
ed the Barthel index. Data were available with maxi-
mum possible follow-up up between 5 and 12 years
from diagnosis. Losses to follow-up in the cohort were
very low: No patient was lost to follow-up regarding
vital status, and only 2 patients were lost to follow-up
for S&E data.
Of the patients, 30 had sustained dependency from
baseline as defined by S&E and 28 as defined by Bar-
thel and were excluded from the analyses. A further 4
and 6 patients were excluded from the analyses
defined by S&E and Barthel, respectively, because
they were independent at baseline and died before
their first follow-up visit. Thus 162 patients were
included in the analyses using the S&E data and 134
patients were included in the analyses using the Bar-
thel data. Those who were dependent at baseline were
older (eg, in the analyses using S&E data, mean age
76.3 vs 71.5 years) but of similar sex distribution
(19% of men and 21% of women).
Probabilities of remaining independent defined by the
2 scales were similar (Fig. 2). Kaplan–Meier probabili-
ties of being dependent by 10 years of follow-up were
nearly 100%. The rate of development of sustained
dependency (defined by S&E) in PD was 13.8 per 100
person years of follow-up (95% confidence interval
[CI] 11.3-16.8) and the median duration of indepen-
dent living after diagnosis of PD was 5.5 years (95%
CI 4.5-5.8). (These figures were very similar when cal-
culated using the Barthel Index to define dependency.)
Within individuals, from year to year there was more
variability in Barthel scores than S&E scores.
Older age at diagnosis, greater smoking history,
more severe axial impairment, and a lower MMSE
score were independently associated with a higher risk
of dependency development defined by the S&E scale;
and in analyses of dependency defined by the Barthel
Index, only older age at diagnosis and severity of axial
impairment were associated with a higher risk of
dependency (Table 2).
Discussion
In summary, in this incident cohort, almost all of
the patients with PD were functionally dependent by
10 years of follow-up. Median duration of indepen-
dent living was 5.5 years. Because of the study design,
this was a predominantly elderly cohort (mean age at
diagnosis 72.5), with relatively few young-onset
patients included. Age, greater smoking history, more
severe axial impairment, and worse cognition were
independent early predictors of greater dependency.
Fewer predictors of dependency were identified using
the Barthel Index than S&E. This may be because of
more year-to-year variability in Barthel scores, which
may be because of the Barthel Index being self-
reported or because not all of the Barthel Index relates
to ADLs (eg, incontinence), although there was also
slightly lower power for the Barthel analyses.
Few previous studies have studied dependency in
PD. One longitudinal study reported dependency using
the S&E scale and found a lower risk of dependency
than in our study (68% at after a mean 11 years of
follow-up).24 A study that defined dependency using
clinical history-taking also found a lower risk of
dependency than in the PINE study (56% at 10
years),3 but another reported a higher risk of depen-
dency (56% at 4 years).25 It is likely that selection
biases and methodological differences explain the
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variation in the rates of dependency rather than true
population differences in dependency risk. None of
these other studies were inception studies (recruiting
all patients from near their diagnoses) or community-
based studies. No previous study has reported longitu-
dinal dependency data derived from the Barthel Index.
No population-based or inception studies have pre-
viously reported risk factors for dependency. Only 2
studies, specialist-clinic-based noninception studies,
have reported predictors for increased dependency
(unlike this study, not measured specifically in early
disease). One of these2 identified male sex, older age,
akinesia rather than tremor, and no response to levo-
dopa (which cannot be assessed at baseline) as inde-
pendent risk factors. However, this study recruited
patients before atypical parkinsonian syndromes were
distinguished from PD, and the paper did not report
hazard ratios for the prognostic factors. The other
study3 reported that dementia, higher Hoehn & Yahr
stage, worse ADL score, and several aspects of the
FIG. 1. Flowchart of participation in the Parkinsonism Incidence in North-East Scotland study. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
TABLE 1. Baseline characteristics
Baseline variable
All patients
(N5 198)
Patients with
Barthel data available
(n5 163)
Mean age in years
at diagnosis (SD)
72.5 (10.4) 72.5 (10.0)
Number male (%) 119 (60) 97 (60)
Median symptom duration
in months (IQR)
13 (9-24) 17 (10-24)
Mean H&Y stage (SD) 2.3 (0.8) 2.3 (0.8)
Mean UPDRS motor score (SD) 25.1 (11.6) 25.4 (11.6)
Mean MMSE (SD) 28.1 (2.3) 28.2 (2.1)
Median Charlson score (IQR) 1 (0-2) 1 (0-2)
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UPDRS scale (rigidity, bradykinesia, postural instabili-
ty, dyskinesia, and total score) were prognostic fac-
tors. However, these prognostic factors were only
independent of age and disease duration and not inde-
pendent of the other prognostic factors studied.
Age was reported as an independent predictor in 1
of these studies, but not in the other. However, age
has consistently been reported as a prognostic factor
for greater activity limitation in general.26-28 One
study3 reported that dementia was associated with a
greater risk of dependency, and other studies have
identified MMSE as a predictor of greater disability in
general.26,27 No previous studies of prognostic factors
for dependency or activity limitation investigated mea-
sures of axial impairment specifically, which was a
stronger prognostic factor than the overall UPDRS
score in this study.
We found that higher levels of smoking history were
associated with more dependency, a finding that has
not previously been reported. Although this finding
was highly significant, it requires replication before we
can be confident that it is not a chance finding. It may
be a result of the effect of smoking-related comorbidi-
ty contributing to dependency, although the baseline
Charlson score was not associated with greater depen-
dency, or perhaps may be due to smokers being more
FIG. 2. Kaplan–Meier probabilities of remaining independent with dependency defined in (A) by the Schwab & England scale and (B) by the Barthel
Index. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
TABLE 2. Associations between baseline characteristics and dependency
Dependency defined by Schwab & England< 80% Dependency defined by Barthel score <19
Baseline variable
Univariable association
with dependency
Multivariable association
with dependencya
Univariable association
with dependency
Multivariable association
with dependencyb
Hazard
ratio (95% CI)
P
value
Hazard
ratio (95% CI)
P
value
Hazard
ratio (95% CI)
P
value
Hazard
ratio (95% CI)
P
value
Age at diagnosis
(10-year increase)
2.57 (1.95-3.39) <.001 2.23 (1.66-2.98) <.001 1.53 (1.19-1.97) .001 1.35 (1.04-1.76) .02
Sex (male vs female) 1.22 (0.82-1.83 .32 0.99 (0.66-1.50) .97 1.15 (0.74-1.78) .53 1.07 (0.69-1.67) .76
DepCat deprivation score 0.99 (0.87-1.12) .87 0.96 (0.84-1.10) .57 0.99 (0.86-1.13) .84 0.97 (0.85-1.12) .70
Smoking history
(10-pack-year increase)
1.18 (1.08-1.28) <.001 1.15 (1.04-1.26) .003 1.04 (0.95-1.13) .38 1.01 (0.92-1.10) .91
Charlson score
(1-point increase)
1.24 (1.08-1.43) .03 1.09 (0.93-1.27) .31 1.10 (0.91-1.34) .32 1.02 (0.84-1.23) .87
Bradykinesia score
(5-point increase)
1.54 (1.24-1.90) <.001 1.21 (0.88-1.66) .24 1.50 (1.18-1.91) .001 1.14 (0.80-1.62) .47
Axial score (5-point increase) 1.28 (1.69-3.06) <.001 1.78 (1.30-2.44) <.001 2.09 (1.51-2.90) <.001 1.85 (1.31-2.62) <.001
UPDRS motor score
(10-unit increase)
1.55 (1.28-1.87) <.001 1.11 (0.77-1.59) .59 1.44 (1.17-1.78) .001 0.91 (0.56-1.40) .67
MMSE score (1-point increase) 0.78 (0.70-0.87) <.001 0.88 (0.79-0.98) .02 0.85 (0.75-0.96) .009 0.95 (0.83-1.08) .41
Hoehn & Yahr stage 1.80 (1.33-2.42) <.001 0.95 (0.63-1.43) .82 1.66 (1.21-2.29) .002 1.06 (0.66-1.68) .82
CI, confidence interval.
aAdjusted for variables in final model: age at diagnosis, smoking history, axial score, and MMSE score.
bAdjusted for variables in final model: age at diagnosis and axial score.
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sedentary.29 This finding provides some evidence
against a neuroprotective effect of smoking as has
been suggested on the basis of lower incidence of PD
in cigarette smokers than in nonsmokers30 and some
experimental data from animal models of PD.31
It was surprising that comorbidity was not associat-
ed with greater dependency, and the only study that
has investigated comorbidity burden as a prognostic
factor in terms of disability in general found that it
was independently predictive on 1 measure of activity
limitation but not another.26 We cannot conclude
from these data that comorbidity is not relevant to
dependency because it may be that the burden of
comorbidity at baseline is less important than the
accrual of comorbidity after diagnosis in terms of the
development of dependency.
The principal strengths of these analyses relate to
the study design, in particular, the use of an inception
cohort, an incident design, a very high consent rate to
follow-up, and very few losses to follow-up; all of
which should lead to low selection bias and high gen-
eralizability to the general population with PD. Other
strengths related to the collection of dependency
data—frequent collection (at least yearly), prospective
collection, near-complete data collection (for S&E
data), and the use of 2 scales with clear face validity
for identifying dependency—have led to a more com-
plete description of the evolution of dependency in PD
than previously reported. We have followed the princi-
ples advocated for the conduct of prognostic factor
studies.32
There are also several limitations that deserve con-
sideration. There was a lack of power to identify
weak associations, and imperfect diagnostic accuracy
is inevitable in any clinical study in PD.33 Neither
scale has been validated as a measurement of depen-
dency, although their validity as an activity limitation
and disability measurement scale have been demon-
strated. Yet, the similar probabilities dependent over
time with both scales provide evidence for the con-
struct validity of these scales to define dependency.
There was internal consistency within the study team
in the way the S&E scale was interpreted, that is,
<80% if dependent on others for basic ADLs, but this
may not be the universal interpretation. Although this
may limit comparisons with raw S&E data from other
studies, it should not limit the generalizability of the
data on predictors of dependency. Because we tried to
recruit all new patients in the population area, this is
predominantly an elderly cohort, with few young-
onset patients (5% aged younger than 50 years). Our
data are therefore mainly based on older-onset PD,
but we are unaware of any data to suggest that the
effects of prognostic factors in PD vary by age.
This work has several benefits, both in clinical prac-
tice and for research. Defining the development of
dependency and identifying its predictors are useful
for providing better information to those affected by
the disease. They can be combined into a prognostic
model to provide individualized risk predictions.34
The development of dependency may also be a useful
outcome measure in clinical trials because it is directly
relevant to patients, is common early in the disease
course in older cohorts, is relatively objective, and
may be less confounded by dopamine replacement
therapy than impairment measures. However, it may
be less useful in young-onset PD. Knowledge of prog-
nostic factors can be used to enhance the design of
clinical trials (eg, to stratify randomization) or as fac-
tors to adjust for in the analysis of trials or observa-
tional studies.32
In conclusion, we have described progression to
dependency and predictors of dependency in a cohort
with a low risk of bias. More research into dependen-
cy is needed (i) to identify which scale is best for mea-
suring dependency, and how best to assess dependency
in instrumental ADLs in PD (which may be more sen-
sitive to early change, especially in younger patients);
(ii) to combine the predictors together to develop and
then validate a prognostic model that would provide
additional value, both for individual risk prediction
and for use in clinical trial design; and (iii) to evaluate
the usefulness of dependency as an outcome in clinical
trials.
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